Trending News

Sickle cells
#Beam Therapeutics #Cell therapy #Phase II trial #Sickle cell disorder (SCD)

Trial results support US biologics license application for risto-cel

Beam Therapeutics has shared positive topline results from the BEACON Phase I/II study evaluating ristoglogene autogetemcel (risto-cel) in patients with sickle cell disease (SCD) with severe vaso-occlusive crises (VOCs).   Risto-cel is an investigational one-time, autologous cell therapy with a potentially differentiated profile for the treatment of SCD. Read More

#News #Trending News

#Epitopea #Immunotherapy #mRNA #Oncology #Ovarian cancer #Phase I trial

First patient receives mRNA immunotherapy for ovarian cancer

The first patient has been successfully dosed in OVACT, Epitopea’s first-in-human Phase I/Ib clinical trial evaluating its lead programme, CryptiVax-1001, targeting advanced high-grade serous ovarian cancer (HGSOC).  OVACT is designed to evaluate the safety, tolerability, immunogenicity, and early clinical activity of CryptiVax-1001 in HRP+/BRCA-wildtype advanced HGSOC patients. … Read More

#Cancer Research #News #Trending News

UK Budget
#Association of the British Pharmaceutical Industry #Investment #Life sciences #UK #UK budget

UK Budget promises £70m for life sciences and lifts VAT on free medicines

In the 2026 Budget, Chancellor John Healey moved to settle a long-running VAT issue that had become a barrier to pharmaceutical companies providing free-of-charge medicines to NHS patients. Medicines supplied free of charge can provide a vital route to treatment for patients with serious conditions. Read More

#Business & Investment #News #Trending News

Gut microbiome
#ESMO #Gut microbiome #Microbiotica #Oncology #Phase I trial

Trial data presented at ESMO support cancer microbiome therapy

Microbiotica has presented clinical data with encouraging efficacy from its Phase Ib MELODY-1 trial of MB097, a precision microbiome therapeutic for patients with advanced melanoma.  The data were presented in a poster at the European Society for Medical Oncology (ESMO) Congress 2026.  The MELODY-1 trial… Read More

#Cancer Research #Editor's Choice #News #Trending News

Cancer cell
#Breast cancer #ESMO #NEC Bio #Oncology #Phase II trial

NEC presents Phase I/II results for individualised oral neoantigen therapy

NEC Bio has presented results from the Phase I/II TNBC clinical trial of its orally administered individualised neoantigen therapy, NECVAX-NEO1, used in combination with checkpoint inhibitors (CPIs) and chemotherapy for patients with triple-negative breast cancer (TNBC).   The findings were presented in an e-poster at the ESMO Congress… Read More

#Cancer Research #News #Trending News

Monoclonal antibodies
#Colorectal cancer #GSK #Immunotherapy #Monoclonal antibodies #Oncology #US Food and Drug Administration (FDA)

FDA approves first immunotherapy for advanced rectal cancer

The US Food and Drug Administration (FDA) has granted accelerated approval for a new use of the immunotherapy Jemperli (dostarlimab-gxly).  The approval is for Jemperli used alone in adults with previously untreated stage II or stage III locally advanced rectal cancer.  Patients with locally advanced… Read More

#Cancer Research #News #Regulatory #Trending News

siRNA
#Merck #Mergers and acquisitions #Silence Therapeutics #siRNA

Merck KGaA buys Silence Therapeutics for $1.3 billion

Merck KGaA is to acquire Silence Therapeutics, a biotechnology company developing precision engineered medicines using siRNA technology.   Merck has agreed to acquire Silence in an all-cash transaction with an enterprise value of $1.1 billion and an equity value of approximately $1.3 billion.  “We are pleased… Read More

#Business & Investment #News #Trending News

#Association of the British Pharmaceutical Industry #MHRA #Regulatory #UK

MHRA reveals 2030 Strategy to modernise patient-centred regulation

The Medicines and Healthcare products Regulatory Agency (MHRA) has published its 2030 Strategy, setting out ambitious plans to translate scientific and technological innovation into better health outcomes.  The regulator says that the commitments will enable it to keep pace with rapid advances in science, technology and personalised… Read More

#News #Regulatory #Trending News

Weight loss concept
#Obesity #Roche #Type 2 diabetes #Weight loss #Zealand Pharma

Roche and Zealand drug shows 9.2% mean body weight reduction

Roche and Zealand Pharma have shared positive topline results from the Phase II ZUPREME-2 trial evaluating petrelintide versus placebo in people living with overweight or obesity and type 2 diabetes.  The trial met its primary endpoint, demonstrating that once-weekly subcutaneous injections of petrelintide (escalated every fourth week)… Read More

#News #Trending News

#Alentis Therapeutics #Collaboration #CSL #Phase II trial

CSL and Alentis announce global partnership

CSL and Alentis Therapeutics have entered into an exclusive global collaboration agreement to co-develop and co-promote lixudebart, which has the potential to become a first-in-class therapy targeting claudin-1 across a range of kidney, liver and other diseases.  Under the terms of the agreement, Alentis will receive a… Read More

#Business & Investment #News #Trending News

Downing Street, London, UK
#Association of the British Pharmaceutical Industry #BioIndustry Association #UK economy

UK groups call on government to back life sciences ambitions in the Budget

Ahead of the Budget, UK life sciences groups have called on the Chancellor to prioritise investment in new medicines.  The UK government has set out bold targets for the UK’s life sciences sector. By 2030, it wants the UK to lead Europe in commercial research and development… Read More

#Business & Investment #News #Trending News

CAR-T cells attack cancer cells
#CAR-T #Cell therapy #Generate Biomedicines #Oncology #Ovarian cancer

First human trials in ovarian cancer for ‘armoured’ CAR-T therapy

Roswell Park Comprehensive Cancer Center and Generate Biomedicines have dosed the first patient in a first-in-human clinical trial evaluating GB-5267, an autologous IL‑18–armoured CAR T-cell therapy.  The therapy is designed to overcome key barriers that have limited the success of cellular therapies in solid tumours.  … Read More

#Cancer Research #News #Trending News

KRAS
#Award #KRAS #Oncology #Pancreatic cancer #Revolution Medicines

$1 million Stephenson Global Prize honours pioneering KRAS research

Kevan Shokat has been named the 2026 Stephenson Global Prize Laureate, receiving $1 million for his pioneering contributions to pancreatic cancer research.   His discoveries helped transform decades of scientific thinking about KRAS, one of cancer’s most important and historically difficult-to-target drivers, and usher in a new generation… Read More

#Cancer Research #News #Trending News

Novartis
#Monoclonal antibodies #Neurodegenerative disorders #Novartis #Phase III trial

Novartis faces September’s fourth trial disappointment with ALS drug

Novartis has revealed plans to pause development of Lifonebart (VHB937), an experimental monoclonal antibody drug targeting the TREM2 protein to treat neurodegenerative diseases.  The news comes just days after the company announced its Phase III trial of antibody oligonucleotide conjugate (AOC) del-desiran had failed.  VHB937… Read More

#News #Trending News

US science protest
#Drug discovery #Funding #National Institutes of Health (NIH) #Politics #United States

Researchers challenge NIH screening of scientific research grants

US researchers have filed a class action lawsuit challenging the National Institutes of Health’s (NIH) policy of blocking grants to censor views it disagrees with, on everything from DEI to gender identity to climate change.  The plaintiffs are represented by the American Civil Liberties Union, the ACLU… Read More

#Editor's Choice #News #Trending News

Lung cancer
#Johnson & Johnson #Lung cancer #Non-small cell lung cancer (NSCLC) #Oncology #Phase III trial

Amivantamab shown to extend survival in advanced NSCLC

Johnson & Johnson has announced final overall survival (OS) results from the Phase III PAPILLON study of first-line intravenous (IV) Rybrevant (amivantamab).  The fully-human EGFR-MET bispecific antibody was assessed with carboplatin-pemetrexed chemotherapy, versus chemotherapy alone, in patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth… Read More

#Cancer Research #News #Trending News